To determine whether extending rituximab dosing intervals to ≥12 months results in higher disease activity compared to standard intervals in persons with relapsing remitting multiple sclerosis (pwRRMS)
No takes yet. Share an insight, caveat, or question.
Langer‐Gould et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: